Safety and efficacy of pramipexole in early Parkinson disease: A randomized dose-ranging study

JAMA

Volumn 278, Issue 2, 1997, Pages 125-130

  Kieburtz, Karl ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VERTIGO;

EID: 0030754066     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.2.125     Document Type: Article

References (18)

1. Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol. 1992;215:161-170.
2. Piercey MF, Camaeho-Ochoa M, Smith MW. Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol. 1995;18(suppl):S34-S42.
3. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol. 1996;312:35-44.
4. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol. 1995;18:338-347.
5. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm Suppl. 1995;45:225-230.
6. Lieberman A. Efficacy and safety of pramipexole in advanced PD patients with the 'wearing-off' phenomenon. Neurology. 1996;46(suppl 2):A475.
7. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology. 1995;45(suppl):S13-S21.
8. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in subjects with early, mild Parkinson's disease: three-year interim report. BMJ. 1993;307:469-472.
9. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five-year follow-up. J Neural Neurosurg Psychiatry. 1994;57:1034-1038.
10. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA. 1996;276:637-639.
11. Rennie D. How to report randomized controlled trials: the CONSORT statement. JAMA 1996; 276: 649.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
13. Folstein MF, Folstein SE, McHugh P. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Paychiatr Res. 1975;12:189-198.
14. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of Neurologic Deficit. Boston, Mass: Butterworth-Heinemann; 1989:285-309.
15. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries, Bermejo F, and The Cooperative Multicentric Group. Unified Parkinson's Disease Rating Scale characteristics and structure. Mov Disord. 1994;9:76-83.
16. van Hilten JJ, van der Zwan AD, Zwinderman AH, Roos RAC. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale. Mov Disord. 1994;9:84-88.
17. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the unified Parkinson's Disease Rating Scale motor examination. Mov Disord. 1994;9:89-91.
18. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD. Teaching tape for the motor section of the Unified Parkinson's Disease Rating Scale. Mov Disord. 1995;10:263-266.